EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Photodynamic therapy in the management of resistant lower urinary tract carcinoma


Cancer 60(12): 3113-3119
Photodynamic therapy in the management of resistant lower urinary tract carcinoma
Twenty-three patients with resistant transitional cell carcinoma (TCC) of the bladder and posterior urethra had photodynamic therapy (PDT). Seventy-two hours after an intravenous injection with 2 mg/kg of the photosensitizer dihematoporphyrin ether (DHE) (Photofrin II, Photomedica, Raritan, NJ), each patient received cystoscopic light treatment. The light dose to the whole bladder using the bulb diffuser ranged from 5 to 60 J/cm2; power density ranged from 9 to 22 mW/cm2. The focal light dose ranged from 100 to 200 J/cm2 at a power density from 100 to 200 mW/cm2. To treat the urethra, a diffuser fiber was used to deliver 200 to 400 J/linear cm at a power of 110 to 300 mW/cm. In the 19 of 23 patients who were treated for resistant superficial TCC, 83.3% of the tumors had responded at the initial follow-up evaluation. Seven patients had a complete response and 10 had a partial response. Three of 19 patients who received inadequate light treatment failed to respond. Control of intractable gross hematuria was the only benefit for patients with locally invasive disease (.gtoreq. T2). Irritating lower urinary tract symptoms that varied in severity and duration occurred in all patients. Four patients experienced bladder shrinkage, which did not resolve. Although the light and drug doses remain to be determined, a whole bladder light dose of 15 to 20 J/cm2 with a drug dose of 2 mg/kg seems to be effective enough without producing permanent adverse effects in the bladder.

Accession: 006110657

PMID: 3677034

DOI: 10.1002/1097-0142(19871215)60:12<3113::aid-cncr2820601242>3.0.co;2-2

Download PDF Full Text: Photodynamic therapy in the management of resistant lower urinary tract carcinoma



Related references

Photodynamic therapy for severe dysplasia and carcinoma in situ of the lower female genital tract. Lasers In Surgery & Medicine: 208, 1986

Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit. Bju International 110(11 Pt B): E596-E600, 2013

Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract. Bju International 109(4): 608-13; Discussion 613-4, 2012

Diagnosis and therapy of upper and lower urinary tract urothelial carcinoma. Progres en Urologie 22(2 Suppl 1): H7-H9, 2012

Lower urinary tract function and pharmacologic management of lower urinary tract dysfunction. Urologic Clinics of North America 14(2): 273-296, 1987

Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. European Urology 67(5): 876-888, 2016

Botulinum toxin therapy for the management of lower urinary tract symptoms – has this come of age?. Drug Discovery Today: Therapeutic Strategies 9(1), 2012

Botulinum toxin injection therapy in the management of lower urinary tract dysfunction. International Journal of Clinical Practice. Supplement: 1-7, 2006

Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. Urology 74(2): 431-435, 2009

Clinical management of lower urinary tract symptoms with combined medical therapy. Bju International 102 Suppl 2: 13-17, 2008